Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is...

Full description

Bibliographic Details
Main Authors:	Davidson, Michael, Smyth, Elizabeth C, Cunningham, David
Format:	Online
Language:	English
Published:	Dove Medical Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966750/

Similar Items

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
by: Maria Angeles Gil-Delgado, et al.
Published: (2018-08-01)

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†
by: Al-Batran, S.-E., et al.
Published: (2016)

Clinical utility of ramucirumab in advanced gastric cancer
by: Chan, Matthew MK, et al.
Published: (2015)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
by: Oholendt, Andrea Landgraf, et al.
Published: (2015)

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
by: Li, Yuhong, et al.
Published: (2015)

Ramucirumab: preclinical research and clinical development
by: Aprile, Giuseppe, et al.
Published: (2014)

The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction
by: Curtis, Nathan J, et al.
Published: (2014)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
by: Li, Minmin, et al.
Published: (2014)

Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
by: Gullo, Irene, et al.
Published: (2015)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
by: ElHalawani, Hesham, et al.
Published: (2015)

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Propper, David, et al.
Published: (2016)

Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
by: Dahle-Smith, Åsa, et al.
Published: (2015)

Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers
by: Dodbiba, Lorin, et al.
Published: (2015)

A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma
by: Mirza, A., et al.
Published: (2013)

Two Cases of Esophageal Eosinophilia: Eosinophilic Esophagitis or Gastro-Esophageal Reflux Disease?
by: Yilmaz, Ozlem, et al.
Published: (2014)

Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction
by: Yaremko, Brian P, et al.
Published: (2013)

Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma
by: Dai, Shu-Qin, et al.
Published: (2013)

Significance of Non-erosive Minimal Esophageal Lesions in Gastro-esophageal Reflux Disorder
by: Hong, Sung-Pyo, et al.
Published: (2004)

The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
by: Shaib, Walid L., et al.
Published: (2016)

Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction
by: Faber, Joyce, et al.
Published: (2015)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
by: HUANG, JUN-XING, et al.
Published: (2013)

FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal–gastric junction
by: Fencl, Pavel, et al.
Published: (2016)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
by: Wainberg, Z A, et al.
Published: (2011)

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
by: Birkman, Eva-Maria, et al.
Published: (2016)

Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas
by: Treese, Christoph, et al.
Published: (2016)

Epstein–Barr Virus in Gastro-Esophageal Adenocarcinomas – Single Center Experiences in the Context of Current Literature
by: Genitsch, Vera, et al.
Published: (2015)

Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors
by: Chow, Laura Q. M., et al.
Published: (2016)

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
by: Fuchs, Charles S, et al.
Published: (2016)

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
by: Tu, Lingli, et al.
Published: (2013)

The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers
by: Huang, Tingting, et al.
Published: (2015)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
by: Cooper, Maryann R, et al.
Published: (2016)

Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma☆
by: Woolston, Caroline M., et al.
Published: (2013)

Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer
by: Fushida, Sachio, et al.
Published: (2015)

Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial
by: Fushida, Sachio, et al.
Published: (2016)

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
by: Camidge, D. Ross, et al.
Published: (2014)

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
by: Janowitz, Tobias, et al.
Published: (2016)

The impact of illness in patients with moderate to severe gastro-esophageal reflux disease
by: El-Dika, Samer, et al.
Published: (2005)

The relationship between helicobacter pylori infection and gastro-esophageal reflux disease
by: Mahdi, Batool M.
Published: (2011)

Traction esophageal diverticulum: a rare cause of gastro-intestinal bleeding
by: Ballehaninna, Umashankar K, et al.
Published: (2012)

Gastro-Esophageal Reflux Disease in Healthy Older Children and Adolescents
by: Park, Kie Young, et al.
Published: (2012)